top of page

The Inno4Vac Scientific and Ethics Advisory Committee has been appointed

August 2023

Inno4Vac announces the nomination of the independent Scientific and Ethics Advisory Committee (SEAC) of the Inno4Vac project.

The Inno4Vac Scientific and Ethics Advisory Committee has been assembled to provide advice and guidance to the Inno4Vac General Assembly and Steering Committee on scientific and ethical issues of the Inno4Vac project.

The high-level board acts independently in key tasks of the Inno4Vac project, supporting scientific strategy and prioritization of project activities, providing advice on ethics/regulatory issues and considerations, European guidelines, and in conflict resolution. Annually, upon request of the Steering Committee, the SEAC prepares a report including recommendations on the scientific advancement of the project as well as an ethical advisory committee report to be submitted to the European Commission as a deliverable.

SEAC Members have been selected and approved by the Steering Committee on the basis of pre-defined criteria to ensure that the composition of the board is appropriate to provide the guidance required to achieve Inno4Vac goals.

The SEAC is currently composed of seven experts in the Inno4Vac topic fields from prestigious universities and research centers, and includes:

  • Ali Ellebedy, Washington University School of Medicine (USA)

  • Maxime M. Mahe, INSERM (FR)

  • Marie-José Quentin-Millet, consultant (FR)

  • Veronique Chatteau, Royal Institute of Technology (SE)

  • Geert Leroux-Roels, Ghent University (BE)

  • Giuseppe del Giudice, consultant (IT)

  • Wayne C. Koff, the Human Vaccines Project (USA)


Additional information on SEAC Members is available at: Scientific and Ethics Advisory Committee | Inno4Vac.

The SEAC will be attending the next Inno4Vac annual meeting, planned in Lyon (FR) on 4-5 October 2023.

 

Contact:

Dr. Irina Meln (Project and Innovation Manager at the European Vaccine Initiative)


This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101007799. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA (www.imi.europa.eu). This communication reflects the author´s view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.

コメント


bottom of page